公开(公告)号：US11219628B2

公开(公告)日：2022-01-11

申请号：US15976630

申请日：2018-05-10

Applicant: AVM BIOTECHNOLOGY, LLC

Inventor： Theresa Deisher

IPC: A61K31/573 ,  A61P35/00 ,  A61K35/17 ,  A61K45/00 ,  A61P37/00 ,  A61P31/18 ,  A61K39/00

Abstract: Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. For example, the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.

公开(公告)号：US20170081641A1

公开(公告)日：2017-03-23

申请号：US15369776

申请日：2016-12-05

Applicant: AVM BIOTECHNOLOGY, LLC

Inventor： Theresa A. Deisher

IPC: C12N5/074

CPC classification number: C12N5/0696 ,  A61K35/545 ,  A61K38/00 ,  A61K39/00 ,  C07K14/00 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/41 ,  C12N2510/02 ,  C12N2517/04

Abstract: Use invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic and(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stern cells to be re-differentiated towards their somatic cell of origin so that the cells can he used to therapeutically treat an animal without resulting teratoma formation.

公开(公告)号：US20240358829A1

公开(公告)日：2024-10-31

申请号：US18683814

申请日：2022-08-31

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher ,  Scot Wayne McKay ,  Vaishnavi Parthasarathy ,  Yumna Zahid

IPC: A61K39/00 ,  A61K31/573 ,  A61P35/00 ,  A61P35/02 ,  A61P37/04 ,  C12N5/0783

CPC classification number: A61K39/4613 ,  A61K31/573 ,  A61P35/00 ,  A61P35/02 ,  A61P37/04 ,  C12N5/0646 ,  A61K2239/38

Abstract: This invention pertains to a novel population of lymphocytes, methods for producing these, and their use in the treatment of diseases.

公开(公告)号：US20200289650A1

公开(公告)日：2020-09-17

申请号：US16885815

申请日：2020-05-28

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher ,  Adalbert Jarzyna ,  Iain Duncan

IPC: A61K47/02 ,  A61K31/573 ,  A61K47/18

Abstract: This invention relates to aqueous pharmaceutical formulations comprising a glucocorticoid. These have been formulated to contain high concentrations of glucocorticoid and reduced levels of preservatives.

公开(公告)号：US20230210868A1

公开(公告)日：2023-07-06

申请号：US17927919

申请日：2021-06-01

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher ,  Scot Wayne McKay

IPC: A61K31/573 ,  A61P35/00

CPC classification number: A61K31/573 ,  A61P35/00

Abstract: This invention pertains to methods of treating cancer and lymphocyte mediated diseases using Intercellular Adhesion Molecule (ICAM)-modulating agents.

公开(公告)号：US10426740B1

公开(公告)日：2019-10-01

申请号：US15973438

申请日：2018-05-07

Applicant: AVM BIOTECHNOLOGY, LLC

Inventor： Theresa Deisher

IPC: A61K31/00 ,  A01N63/00 ,  C12N5/00 ,  A61K45/06 ,  C07K16/28 ,  A61K35/28 ,  A61K31/573 ,  A61K38/13 ,  C12N5/071 ,  A61K35/12

Abstract: The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.

公开(公告)号：US20230172950A1

公开(公告)日：2023-06-08

申请号：US17921128

申请日：2021-04-28

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher ,  Scot Wayne McKay

IPC: A61K31/573 ,  A61P31/14

CPC classification number: A61K31/573 ,  A61P31/14

Abstract: The present disclosure relates to novel therapies and associated methods of treatment based on newly provided therapeutic mechanisms mediated by the binding of glucocorticoids to intercellular adhesion molecules (ICAMs).

公开(公告)号：US20180296572A1

公开(公告)日：2018-10-18

申请号：US15976630

申请日：2018-05-10

Applicant: AVM BIOTECHNOLOGY, LLC

Inventor： Theresa DEISHER

IPC: A61K31/573 ,  A61P35/00 ,  A61P37/00 ,  A61P31/18 ,  A61K39/00

Abstract: Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More specifically the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.

公开(公告)号：US10030230B2

公开(公告)日：2018-07-24

申请号：US15369776

申请日：2016-12-05

Applicant: AVM BIOTECHNOLOGY, LLC

Inventor： Theresa A. Deisher

IPC: C12N5/074 ,  C12N5/075 ,  A61K35/545 ,  A61K38/00 ,  A61K39/00 ,  C07K14/00 ,  C07K16/00

Abstract: Use invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.

公开(公告)号：US12048705B2

公开(公告)日：2024-07-30

申请号：US17281016

申请日：2019-10-03

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher

IPC: A61K31/573 ,  A61K9/00 ,  A61K47/54 ,  A61P3/10 ,  A61P25/14 ,  A61P31/18 ,  A61P35/00 ,  A61P37/06 ,  C07K16/42

CPC classification number: A61K31/573 ,  A61K9/0019 ,  A61K9/0053 ,  A61K47/547 ,  A61P3/10 ,  A61P25/14 ,  A61P31/18 ,  A61P35/00 ,  A61P37/06 ,  C07K16/4283

Abstract: This invention pertains to pharmaceutical compositions comprising a glucocorticoid for use in the treatment of diseases by immunoablation. The compositions of the invention may be for use in the treatment of diseases that are mediated by immune cells such as lymphocytes.